PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
9835525-9	1998	The addition of CAP18106-137 to aztreonam along with the bacteria did decrease the level of antibiotic-induced release of inflammatory mediators including tumor necrosis factor alpha, interleukin-6, and nitric oxide and also improved the survival of the mice.	Aztreonam	32-41	tumor necrosis factor	Mus musculus	155-182	
12935353-2	2003	Ceftazidime and aztreonam enhanced TNF-alpha secretion from macrophages stimulated with E. coli; however, imipenem does not alter either the kinetics or magnitude of TNF-alpha in E. coli-treated macrophages.	Aztreonam	16-25	tumor necrosis factor	Mus musculus	35-44	
12935353-6	2003	Both ceftazidime and aztreonam enhanced LPS release from E. coli in comparison to low-level LPS release from imipenem-treated bacteria, consistent with observed differences in TNF-alpha release.	Aztreonam	21-30	tumor necrosis factor	Mus musculus	176-185	
9529499-9	1998	Both continuous metronidazole and aztreonam reduced lung MPO concentration (P < 0.05) and TNF-alpha and IL-1 beta mRNA expression (P < 0.05) compared with those in saline controls.	Aztreonam	34-43	tumor necrosis factor	Mus musculus	93-102